Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OTLKW

Outlook Therapeutics (OTLKW)

Outlook Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OTLKW
DateTimeSourceHeadlineSymbolCompany
06/11/20249:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
05/28/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
05/15/20245:00PMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
05/13/20248:50AMGlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
05/09/20248:45AMGlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKWOutlook Therapeutics Inc
05/02/20249:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKWOutlook Therapeutics Inc
04/29/20249:00AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKWOutlook Therapeutics Inc
04/15/20244:15PMGlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
03/22/20247:35AMGlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
03/18/20245:10PMGlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
03/12/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKWOutlook Therapeutics Inc
02/14/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
01/31/20248:05AMGlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKWOutlook Therapeutics Inc
01/23/20248:00AMGlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
12/22/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKWOutlook Therapeutics Inc
12/19/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
12/06/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKWOutlook Therapeutics Inc
11/27/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
11/14/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of EuropeNASDAQ:OTLKWOutlook Therapeutics Inc
11/02/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Provides Update on Type A Meetings with FDANASDAQ:OTLKWOutlook Therapeutics Inc
11/01/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
09/29/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Requests Type A Meeting With FDANASDAQ:OTLKWOutlook Therapeutics Inc
09/21/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
09/05/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
08/30/20236:00AMGlobeNewswire Inc.Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
08/14/20238:05AMGlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term MilestonesNASDAQ:OTLKWOutlook Therapeutics Inc
08/01/20238:45AMGlobeNewswire Inc.Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023NASDAQ:OTLKWOutlook Therapeutics Inc
05/16/20237:10AMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:OTLKWOutlook Therapeutics Inc
05/16/20236:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OTLKWOutlook Therapeutics Inc
05/15/20234:51PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OTLKWOutlook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OTLKW